[A21-90] Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Last updated 01.10.2021

Project no.:
A21-90

Commission:
Commission awarded on 01.07.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Treatment of adults with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy

Result of dossier assessment:
  • Patients without prior stem cell therapy: Indication of major added benefit.
  • Patients with prior stem cell therapy: added benefit not proven.
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

informedhealth.org logo Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form